Lannett Bets On Respiratory And Insulins Pipeline As Sales Falter

Advair And Flovent Rivals And Biosimilar Insulins Among ‘Durable’ Opportunities

 
• By David Wallace
  
Pipeline Mountains Rocks
Amid rocky Q3 results, Lannett is banking on its pipeline • Source: Alamy

More from Earnings

More from Business